Bick David, Ahmed Arzoo, Deen Dasha, Ferlini Alessandra, Garnier Nicolas, Kasperaviciute Dalia, Leblond Mathilde, Pichini Amanda, Rendon Augusto, Satija Aditi, Tuff-Lacey Alice, Scott Richard H
Genomics England Ltd., Dawson Hall, Charterhouse Square, Barbican, London EC1M 6BQ, UK.
Medical Genetics Unit, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy.
Int J Neonatal Screen. 2022 Jul 15;8(3):40. doi: 10.3390/ijns8030040.
Newborn screening for treatable disorders is one of the great public health success stories of the twentieth century worldwide. This commentary examines the potential use of a new technology, next generation sequencing, in newborn screening through the lens of the Wilson and Jungner criteria. Each of the ten criteria are examined to show how they might be applied by programmes using genomic sequencing as a screening tool. While there are obvious advantages to a method that can examine all disease-causing genes in a single assay at an ever-diminishing cost, implementation of genomic sequencing at scale presents numerous challenges, some which are intrinsic to screening for rare disease and some specifically linked to genomics-led screening. In addition to questions specific to routine screening considerations, the ethical, communication, data management, legal, and social implications of genomic screening programmes require consideration.
对可治疗疾病进行新生儿筛查是20世纪全球公共卫生领域的重大成功案例之一。本评论通过威尔逊和荣格纳标准审视了新一代测序这项新技术在新生儿筛查中的潜在应用。对十条标准中的每一条都进行了审视,以展示使用基因组测序作为筛查工具的项目可能如何应用这些标准。虽然一种能够以不断降低的成本在一次检测中检测所有致病基因的方法具有明显优势,但大规模实施基因组测序也带来了诸多挑战,其中一些是罕见病筛查所固有的,还有一些则与基因组学主导的筛查具体相关。除了常规筛查考虑因素特有的问题外,基因组筛查项目的伦理、沟通、数据管理、法律和社会影响也需要加以考虑。